Positive high-level results from the EMERALD-3 phase III trial showed AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab), lenvatinib and transarterial chemoembolisation (TACE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results